TNSN07294A1 - Treatment of metastasized tumors - Google Patents

Treatment of metastasized tumors

Info

Publication number
TNSN07294A1
TNSN07294A1 TNP2007000294A TNSN07294A TNSN07294A1 TN SN07294 A1 TNSN07294 A1 TN SN07294A1 TN P2007000294 A TNP2007000294 A TN P2007000294A TN SN07294 A TNSN07294 A TN SN07294A TN SN07294 A1 TNSN07294 A1 TN SN07294A1
Authority
TN
Tunisia
Prior art keywords
compound
tautomer
treatment
metastasized tumors
salt
Prior art date
Application number
TNP2007000294A
Other languages
English (en)
Inventor
De Menezes Daniel Lopes
Carla Heise
Xiaohua Xin
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36741085&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TNSN07294(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of TNSN07294A1 publication Critical patent/TNSN07294A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
TNP2007000294A 2005-01-27 2007-07-27 Treatment of metastasized tumors TNSN07294A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US64756805P 2005-01-27 2005-01-27
US66924505P 2005-04-06 2005-04-06
US72205305P 2005-09-29 2005-09-29
PCT/US2006/002979 WO2006081445A2 (en) 2005-01-27 2006-01-27 Treatment of metastasized tumors

Publications (1)

Publication Number Publication Date
TNSN07294A1 true TNSN07294A1 (en) 2008-12-31

Family

ID=36741085

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2007000294A TNSN07294A1 (en) 2005-01-27 2007-07-27 Treatment of metastasized tumors

Country Status (22)

Country Link
US (2) US20060183750A1 (https=)
EP (2) EP1845990B1 (https=)
JP (2) JP5371246B2 (https=)
KR (1) KR101387985B1 (https=)
CN (1) CN103893181A (https=)
AT (1) ATE526025T1 (https=)
AU (1) AU2006208012B2 (https=)
BR (1) BRPI0607285A2 (https=)
CA (1) CA2596084A1 (https=)
CY (1) CY1112570T1 (https=)
DK (1) DK1845990T3 (https=)
ES (2) ES2374570T3 (https=)
IL (1) IL184866A0 (https=)
MA (1) MA29266B1 (https=)
MX (1) MX2007009099A (https=)
NO (1) NO20074360L (https=)
PL (2) PL1845990T3 (https=)
PT (2) PT2301546E (https=)
SG (1) SG173317A1 (https=)
SI (1) SI2301546T1 (https=)
TN (1) TNSN07294A1 (https=)
WO (1) WO2006081445A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1313734B1 (en) 2000-09-01 2009-11-11 Novartis Vaccines and Diagnostics, Inc. Aza heterocyclic derivatives and their therapeutic use
CZ304344B6 (cs) 2000-09-11 2014-03-19 Novartis Vaccines & Diagnostics, Inc. Chinolinonový derivát a jeho použití a farmaceutický prostředek s obsahem tohoto derivátu
CA2496164C (en) 2002-08-23 2010-11-09 Chiron Corporation Benzimidazole quinolinones and uses thereof
CA2608171C (en) * 2005-05-13 2014-02-04 Novartis Ag Use of quinolinone compounds for treating drug resistant cancers
MX2007014782A (es) * 2005-05-23 2008-02-19 Novartis Ag Formas cristalinas y otras formas de las sales de acido lactico de 4-amino-5-fluoro-3-[6-(4-metilpiperazin-1-il)-1h-bencimidazol-2 -il]-1h quinolin-2-ona.
PE20091628A1 (es) * 2008-03-19 2009-11-19 Novartis Ag Formas cristalinas y dos formas solvatadas de sales de acido lactico de 4-amino-5-fluoro-3-[5-(4-metilpiperazin-1-il)-1h-benzimidazol-2-il]quinolin-2(1h)-ona
EP2432451A2 (en) * 2009-05-20 2012-03-28 Children's Medical Center Corporation Compositions for the treatment of metastatic cancer and methods of use thereof
ES2707625T3 (es) * 2010-04-16 2019-04-04 Novartis Ag Compuesto orgánico para su utilización en el tratamiento del cáncer de hígado
BR112013029246A2 (pt) * 2011-05-19 2017-02-14 Novartis Ag 4-amino-5-flúor-3-[6- (4-metilpiperazin- 1 - il) - 1h - benzimidazol - 2 - il] - 1h - quinolin-2-ona para uso no tratamento de carcinoma adenoide cístico
JP2015505562A (ja) * 2012-01-31 2015-02-23 ノバルティス アーゲー Ｒｔｋ阻害剤と抗エストロゲン剤との組合せ、およびがん治療のためのその使用
KR102494647B1 (ko) * 2016-07-14 2023-01-31 브리스톨-마이어스 스큅 컴퍼니 비시클릭 헤테로아릴 치환된 화합물

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3663606A (en) * 1966-06-21 1972-05-16 Mitsui Toatsu Chemicals Organic imino-compounds
DE2363459A1 (de) 1973-12-20 1975-06-26 Basf Ag Neue fluoreszierende chinolinverbindungen
US4659657A (en) * 1982-12-24 1987-04-21 Bayer Aktiengesellschaft Chromogenic and fluorogenic esters for photometric or fluorimetric determination of phosphatases or sulphatases
US5073492A (en) * 1987-01-09 1991-12-17 The Johns Hopkins University Synergistic composition for endothelial cell growth
JPH0699497B2 (ja) 1987-04-16 1994-12-07 富士写真フイルム株式会社 光重合性組成物
DE3932953A1 (de) * 1989-10-03 1991-04-11 Boehringer Mannheim Gmbh Neue 2-bicyclo-benzimidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
GB9108547D0 (en) 1991-04-22 1991-06-05 Fujisawa Pharmaceutical Co Quinoline derivatives
US5480883A (en) * 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5710158A (en) * 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
USRE37650E1 (en) * 1991-05-10 2002-04-09 Aventis Pharmacetical Products, Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
US5856115A (en) * 1991-05-24 1999-01-05 Fred Hutchinson Cancer Research Center Assay for identification therapeutic agents
EP1306095A3 (en) * 1992-03-05 2003-06-25 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
JP3142378B2 (ja) 1992-06-22 2001-03-07 ティーディーケイ株式会社 有機ｅｌ素子
US5981569A (en) * 1992-11-13 1999-11-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Substituted phenylacrylonitrile compounds and compositions thereof for the treatment of disease
US5763441A (en) * 1992-11-13 1998-06-09 Sugen, Inc. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
US5792771A (en) * 1992-11-13 1998-08-11 Sugen, Inc. Quinazoline compounds and compositions thereof for the treatment of disease
JPH0743896A (ja) 1993-07-28 1995-02-14 Toyobo Co Ltd 光重合性組成物
JPH0829973A (ja) 1994-07-11 1996-02-02 Toyobo Co Ltd 光重合性組成物
JP3441246B2 (ja) 1995-06-07 2003-08-25 富士写真フイルム株式会社 光重合性組成物
GB9624482D0 (en) * 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
DE19610723A1 (de) 1996-03-19 1997-09-25 Bayer Ag Elektrolumineszierende Anordnungen unter Verwendung von Blendsystemen
US5942385A (en) * 1996-03-21 1999-08-24 Sugen, Inc. Method for molecular diagnosis of tumor angiogenesis and metastasis
CA2258728C (en) * 1996-06-19 2011-09-27 Rhone Poulenc Rorer Limited Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
HUP9904567A3 (en) 1996-06-20 2001-10-29 Univ Texas Use of azo, thioalkyl, thiocarbonyl derivatives substituted by fused heterocycles and/or phenyl group for the preparation of pharmaceutical compositions stimulating bone growth
US6111110A (en) * 1996-10-30 2000-08-29 Eli Lilly And Company Synthesis of benzo[f]quinolinones
AU778042B2 (en) 1999-10-19 2004-11-11 Merck & Co., Inc. Tyrosine kinase inhibitors
HRP20020349A2 (en) * 1999-10-19 2004-02-29 Merck & Co Inc Tyrosine kinase inhibitors
US6313138B1 (en) * 2000-02-25 2001-11-06 Merck & Co., Inc. Tyrosine kinase inhibitors
AU778417B2 (en) 2000-02-25 2004-12-02 Merck & Co., Inc. Tyrosine kinase inhibitors
US6420382B2 (en) 2000-02-25 2002-07-16 Merck & Co., Inc. Tyrosine kinase inhibitors
EP1313734B1 (en) * 2000-09-01 2009-11-11 Novartis Vaccines and Diagnostics, Inc. Aza heterocyclic derivatives and their therapeutic use
WO2002020500A2 (en) * 2000-09-01 2002-03-14 Icos Corporation Materials and methods to potentiate cancer treatment
CZ304344B6 (cs) 2000-09-11 2014-03-19 Novartis Vaccines & Diagnostics, Inc. Chinolinonový derivát a jeho použití a farmaceutický prostředek s obsahem tohoto derivátu
US20030028018A1 (en) * 2000-09-11 2003-02-06 Chiron Coporation Quinolinone derivatives
US7064215B2 (en) * 2001-07-03 2006-06-20 Chiron Corporation Indazole benzimidazole compounds
US7825132B2 (en) * 2002-08-23 2010-11-02 Novartis Vaccines And Diagnostics, Inc. Inhibition of FGFR3 and treatment of multiple myeloma
CA2496164C (en) * 2002-08-23 2010-11-09 Chiron Corporation Benzimidazole quinolinones and uses thereof
AU2003290699B2 (en) * 2002-11-13 2009-08-27 Novartis Vaccines And Diagnostics, Inc. Methods of treating cancer and related methods
US6774327B1 (en) * 2003-09-24 2004-08-10 Agilent Technologies, Inc. Hermetic seals for electronic components
CN102225926A (zh) * 2003-11-07 2011-10-26 诺华疫苗和诊断公司 具有改进药物特性的喹啉酮类化合物的药学上可接受的盐
US7875624B2 (en) * 2004-02-20 2011-01-25 Novartis Vaccines And Diagnostics, Inc. Modulating and measuring cellular adhesion
BRPI0613200A2 (pt) * 2005-05-18 2012-01-03 M & G Polimeri Italia Spa composiÇço de poliÉster
KR102639757B1 (ko) 2017-01-09 2024-02-23 엘지이노텍 주식회사 카메라 모듈 및 이를 포함하는 광학기기

Also Published As

Publication number Publication date
BRPI0607285A2 (pt) 2009-08-25
IL184866A0 (en) 2007-12-03
PL2301546T3 (pl) 2015-03-31
WO2006081445A3 (en) 2007-01-11
JP5371246B2 (ja) 2013-12-18
EP1845990A2 (en) 2007-10-24
CA2596084A1 (en) 2006-08-03
MX2007009099A (es) 2007-09-13
EP1845990B1 (en) 2011-09-28
PT1845990E (pt) 2011-12-23
HK1155664A1 (en) 2012-05-25
ES2525670T3 (es) 2014-12-29
DK1845990T3 (da) 2012-01-02
EP2301546A1 (en) 2011-03-30
JP2008528617A (ja) 2008-07-31
ES2374570T3 (es) 2012-02-17
WO2006081445A2 (en) 2006-08-03
KR20070118596A (ko) 2007-12-17
MA29266B1 (fr) 2008-02-01
ATE526025T1 (de) 2011-10-15
PT2301546E (pt) 2014-12-18
US20100173873A1 (en) 2010-07-08
US20060183750A1 (en) 2006-08-17
EP1845990A4 (en) 2008-04-30
NO20074360L (no) 2007-10-25
AU2006208012A1 (en) 2006-08-03
SI2301546T1 (sl) 2015-01-30
AU2006208012B2 (en) 2011-08-04
CN103893181A (zh) 2014-07-02
JP2013177464A (ja) 2013-09-09
PL1845990T3 (pl) 2012-02-29
EP2301546B1 (en) 2014-09-10
KR101387985B1 (ko) 2014-04-25
SG173317A1 (en) 2011-08-29
CY1112570T1 (el) 2016-02-10

Similar Documents

Publication Publication Date Title
TNSN07294A1 (en) Treatment of metastasized tumors
MX2009009574A (es) Tratamiento de melanoma.
MX2007009649A (es) Derivados de meleimida, composiciones farmaceuticas y metodos para el tratamiento del cancer.
MX2007002398A (es) Nuevas composiciones farmaceuticas para el tratamiento de cancer.
MX2009006742A (es) Inhibidores acilaminopirazoles como fgfr.
MY191349A (en) New pharmaceutical compositions for the treatment of hyper-proliferative disorders
TNSN07341A1 (en) Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer
WO2005110994A8 (en) Substituted pyrazolyl urea derivatives useful in the treatment of cancer
WO2008127594A3 (en) Combination therapies comprising quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer
EA201100971A1 (ru) Производные пиримидининдола для лечения злокачественного новообразования
WO2009067397A3 (en) Treatment for solid tumors
TNSN07419A1 (en) Methods for treating drug resistant cancer
WO2005004808A3 (en) TETRACYCLIC COMPOUNDS AS c-MET INHIBITORS
WO2007038868A3 (en) Novel enediyne compound and uses thereof
WO2010121675A3 (en) Thiazolyl-benzimidazoles
WO2006044975A3 (en) Compositions and their use as anti-tumor agents
WO2005085188A3 (en) Compounds and methods for anti-tumor therapy
WO2007076087A3 (en) 3-aryl-substituted quinazolones, and uses thereof
WO2010014798A3 (en) Pyrimidotriazinediones and pyrimidopyrimidinediones and methods of using the same
GB0305928D0 (en) Organic compounds
TW200727904A (en) Method of administration for 5-(2-chlorophenyl)-1,2-dihydro-7-fluoro-8-methoxy-3-methyl-pyrazolo[3,4-b][1,4]benzodiazepine
UA98508C2 (ru) Иммуномодуляторное производное дипептида для лечения рака легких
WO2007017652A3 (en) Arylakylamines for the treatment of cancer
MY148385A (en) Maleimide derivatives, pharmaceutical compositions and methods for treatment of cancer
MY140324A (en) Maleimide derivatives, pharmaceutical compositions and methods for treatment of cancer